

Press Release

October 18, 2017

Company Name: Eiken Chemical Co., Ltd.
Representative: Morifumi Wada, President & CEO
Securities code: 4549 (TSE 1st Section)

Determined to provide reagents for Australia's National Bowel Cancer Screening Program

Eiken Chemical Co., Ltd. (Head office in Taito-ku, Tokyo) sells worldwide fecal immunochemical test reagents (OC-Auto, etc) and fully automated fecal occult blood analyzers (OC-Sensor) used in the bowel cancer screening test as the core products for overseas market, in the pursuit of transformation of EIKEN into a global corporation.

We were notified that it had been decided by the Australian government to contract Sonic Healthcare Limited (clinical diagnostics laboratory) to provide the immunological fecal occult blood test for Australia's National Bowel Cancer Screening Program. Sonic Healthcare Limited plans to adopt our reagents and analyzers for this program implementation. The new test will be introduced into the bowel cancer screening program throughout Australia from January 2018.

Our management philosophy is to "protect the health of the public through health care services." We will continue to contribute to the health of people through the supply of our products and expertise.

For inquiries :

Eiken Chemical Co., Ltd., Public Relations Section

e-mail: koho@eiken.co.jp

URL: <http://www.eiken.co.jp/en/>